Path loss model for outdoor parking environments at 28 GHz and 38 GHz for 5G wireless networks

It has been widely speculated that the performance of the next generation Internet of Things (IoT) based wireless network should meet a transmission speed on the order of 1000 times more than current wireless networks; energy consumption on the order of 10 times less and access delay of less than 1 ns that will be provided by future 5G systems. To increase the current mobile broadband capacity in future 5G systems, the millimeter wave (mmWave) band will be used with huge amounts of bandwidth available in this band. Hence, to support this wider bandwith at the mmWave band, new radio access technology (RAT) should be provided for 5G systems. The new RAT with symmetry design for downlink and uplink should support different scenarios such as device to device (D2D) and multi-hop communications. This paper presents the path loss models in parking lot environment which represents the multi-end users for future 5G applications. To completely assess the typical performance of 5G wireless network systems across these different frequency bands, it is necessary to develop path loss (PL) models across these wide frequency ranges. The short wavelength of the highest frequency bands provides many scatterings from different objects. Cars and other objects are some examples of scatterings, which represent a critical issue at millimeter-wave bands. This paper presents the large-scale propagation characteristics for millimeter-wave in a parking lot environment. A new physical-based path loss model for parking lots is proposed. The path loss was investigated based on different models. The measurement was conducted at 28 GHz and 38 GHz frequencies for different scenarios. Results showed that the path loss exponent values were approximately identical at 28 GHz and 38 GHz for different scenarios of parking lots. It was found that the proposed compensation factor varied between 10.6 dB and 23.1 dB and between 13.1 and 19.1 in 28 GHz and 38 GHz, respectively. The proposed path loss models showed that more compensation factors are required for more scattering objects, especially at 28 GHz

Electronic and NLO Performances of Benzohydrazide Derivatives: DFT Investigation and (RDG, AIM) Analysis

International audienceDFT calculations of ground-state hydrazine and benzohydrazide derivatives were performed by using hybrid functional B3LYP and CAMB3LYP with 6–31G (d, p) as basis set. The electric dipole moment (μ), polarizability (α) and molecular first hyperpolarizability (β) were characterized in these compounds. The HOMO–LUMO energy gaps and the global chemical reactivity descriptors were computed by B3LYP and CAMB3LYP using 6–31G (d,p), while the excitation energies have determined by time dependent DFT (TDDFT). Besides, the stability and charge delocalization were studied by natural bond orbital analysis. Topological analyses such as atom in molecule (AIM), natural bonding orbital (NBO) and molecular electrostatic potential (MEP) have used to compute intermolecular interactions and in particular hydrogen bonds. The obtained first-order hyperpolarizabilities in the range of 1.5 × 10−30 to 30.2 × 10−30 esu revealed that the hydrazine and benzohydrazide derivatives have better NLO properties. The low-energy gap of 3.53 eV generates an intramolecular charge transfer, leading to the enhancement of the NLO activity in these compounds

Enhanced infection prophylaxis reduces mortality in severely immunosuppressed HIV-infected adults and older children initiating antiretroviral therapy in Kenya, Malawi, Uganda and Zimbabwe: the REALITY trial

Meeting abstract FRAB0101LB from 21st International AIDS Conference 18–22 July 2016, Durban, South Africa. Introduction: Mortality from infections is high in the first 6 months of antiretroviral therapy (ART) among HIV‐infected adults and children with advanced disease in sub‐Saharan Africa. Whether an enhanced package of infection prophylaxis at ART initiation would reduce mortality is unknown. Methods: The REALITY 2×2×2 factorial open‐label trial (ISRCTN43622374) randomized ART‐naïve HIV‐infected adults and children >5 years with CD4 <100 cells/mm3. This randomization compared initiating ART with enhanced prophylaxis (continuous cotrimoxazole plus 12 weeks isoniazid/pyridoxine (anti‐tuberculosis) and fluconazole (anti‐cryptococcal/candida), 5 days azithromycin (anti‐bacterial/protozoal) and single‐dose albendazole (anti‐helminth)), versus standard‐of‐care cotrimoxazole. Isoniazid/pyridoxine/cotrimoxazole was formulated as a scored fixed‐dose combination. Two other randomizations investigated 12‐week adjunctive raltegravir or supplementary food. The primary endpoint was 24‐week mortality. Results: 1805 eligible adults (n = 1733; 96.0%) and children/adolescents (n = 72; 4.0%) (median 36 years; 53.2% male) were randomized to enhanced (n = 906) or standard prophylaxis (n = 899) and followed for 48 weeks (3.8% loss‐to‐follow‐up). Median baseline CD4 was 36 cells/mm3 (IQR: 16–62) but 47.3% were WHO Stage 1/2. 80 (8.9%) enhanced versus 108(12.2%) standard prophylaxis died before 24 weeks (adjusted hazard ratio (aHR) = 0.73 (95% CI: 0.54–0.97) p = 0.03; Figure 1) and 98(11.0%) versus 127(14.4%) respectively died before 48 weeks (aHR = 0.75 (0.58–0.98) p = 0.04), with no evidence of interaction with the two other randomizations (p > 0.8). Enhanced prophylaxis significantly reduced incidence of tuberculosis (p = 0.02), cryptococcal disease (p = 0.01), oral/oesophageal candidiasis (p = 0.02), deaths of unknown cause (p = 0.02) and (marginally) hospitalisations (p = 0.06) but not presumed severe bacterial infections (p = 0.38). Serious and grade 4 adverse events were marginally less common with enhanced prophylaxis (p = 0.06). CD4 increases and VL suppression were similar between groups (p > 0.2). Conclusions: Enhanced infection prophylaxis at ART initiation reduces early mortality by 25% among HIV‐infected adults and children with advanced disease. The pill burden did not adversely affect VL suppression. Policy makers should consider adopting and implementing this low‐cost broad infection prevention package which could save 3.3 lives for every 100 individuals treated